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In vitro studies have shown that gastroenteropancreatic tumors, with the excep-
tion of insulinomas, have a high density of somatostatin receptors and can be
imaged in vivo using somatostatin receptor scintigraphy (SRS) with either [l23I1
Tyr ]octreotide or [1IIn DTPA,DPhe ]octreotide. However, the sensitivity in
relation to conventional imaging studies (ultrasound, CT, MRI, angiography)
remains unclear. To address this question, we performed a prospective study of
80 patients with gastrinomas where SRS was compared with other convention-
al imaging techniques for detecting extrahepatic gastrinomas or liver metas-
tases. Extrahepatic gastrinomas were identified by SRS in 58 percent of
patients, whereas conventional imaging studies detected gastrinomas in 9 per-
cent to48 percent ofpatients. In detecting hepatic metastases in 24 patients with
histologically-proven metastases, SRS was positive in 92 percent; ultrasound,
CT or angiography in 42 percent to 62 percent; and MRI in 71 percent of
patients. These results are compared with other studies in detecting gastrinomas
as well as series including otherPETs, excluding insulinomas, with insulinomas
alone, and with carcinoid tumors. An analysis of the ability of SRS to identify
gastrinomas found in different sites at surgery wasperformed. Therole ofendo-
scopic ultrasound (EUS) in detecting various PETs, in comparison to that of
SRS, is yet to be established, particularly for extrapancreatic PETs. Therefore,
the results of EUS in various studies containing patients with PETs are com-
pared to those with SRS and conventional imaging studies. These data suggest
that EUS is the first choice of localization methods for detecting insulinoma,
which is an intrapancreatic tumor in almost all cases. In other PETs there still is
not sufficient data to establish the relative roles ofEUS and SRS.
INTRODUCTION
Imaging studies are essential for planning an appropriate strategy in the man-
agement of gastrointestinal neuroendocrine tumors, carcinoid tumors and pancreatic
endocrine tumors (PETs)b [1-3]. A number of conventional imaging methods such as
ultrasound, computed tomographic scanning (CT), magnetic resonance imaging (MRI)
and selective angiography [1, 2, 4-6], and for functional neuroendocrine tumors, func-
tional localization methods have been recommended, such as portal venous sampling for
hormonal gradients and selective intra-arterial provocative tests with hepatic venous sam-
pling for hormone concentrations [7-10]. For carcinoid tumors, either conventional imag-
ing methods, gastrointestinal barium studies and/or endoscopy are generally used [2, 3].
These studies generally show that selective angiography and MRI are the most sensitive
a To whom all correspondence should be addressed: Robert T. Jensen, M.D., NIH/NIDDK/DDB,
Bldg. 10, Rm. 9C-103, 10 Center DR MSC 1804, Bethesda, Maryland 20892-1804. Tel.: (301) 96-
4201; Fax: (301) 402-0600; E-mail: robtj@bdglO.niddk.nih.gov.
bAbbreviations: CT, computerized tomographic scanning; EUS, endoscopic ultrasound; MRI, mag-
netic resonance imaging; PET, pancreatic endocrine tumor; SRS, somatostatin receptor scintigra-
phy; STIR, short-time inversion recovery sequence.
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modalities [1, 7, 9, 11]; however, they still fail to identify the primary in up to 50 percent
ofpatients in some studies [1, 6, 12].
Recently, two newer localization methods using somatostatin receptor scintigraphy
(SRS) or endoscopic ultrasound (EUS) are increasingly recommended. Several recent
studies reported that SRS is superior to some conventional imaging studies in localizing
gastrointestinal neuroendocrine tumors [13-21]. However, the information on SRS sensi-
tivity compared with that ofother imaging techniques is limited in most studies in various
ways. Until recently the number ofpatients studied in the different series was small. Only
a few studies compared SRS systematically with that ofmost sensitive conventional imag-
ing methods, particularly selective angiography and MRI using STIR (short-time inver-
sion-recovery sequences) [1, 6, 11]. The assessment of tumor detection was often on a
lesion-by-lesion basis, and therefore, it was difficult to relate it to a given patient's man-
agement. Finally, many studies did not assess the sensitivity ofSRS relative to other meth-
ods in different clinical situations such as whether localization methods were being used
to identify a primary tumor or whether the localization studies were being performed to
identify metastatic disease. This latter point is particularly important because some local-
ization methods are better for localizing primary tumors, whereas other are used primari-
ly to localize metastatic disease in the liver [1, 4, 11, 22-24]. Recently, endoscopic ultra-
sound has been increasingly used for localization ofPETs and reported to be more sensi-
tive than conventional imaging methods in detecting PETs, with its sensitivity reaching 94
percent in some series [23, 25-33]. At present, only a few studies have compared the rel-
ative sensitivity ofendoscopic ultrasound to the SRS in localizing PETs [23, 27, 28], and
the experience with nonfunctional or carcinoid tumor is even more limited. At present the
relative roles of EUS and SRS in localization of PETs is unclear and controversial.
Recently, we have begun prospective studies to address both the sensitivity of SRS
compared to conventional imaging studies and the sensitivity of endoscopic ultrasound
compared to other tumor localization modalities in patients with gastrinomas. The first
study is now completed and in this paper we will review the methods, results, and impli-
cations of this study. The NIH endoscopic ultrasound study isjust beginning. Thus, in the
latter part of this paper, the recent data from other centers on the use ofendoscopic ultra-
sound to localize gastrointestinal neuroendocrine tumors will be reviewed briefly.
NIH STUDY ON THE COMPARATIVE SENSITIVITY OF SRS AND
CONVENTIONAL IMAGING STUDIES IN LOCALIZING GASTRINOMAS
In this study we prospectively compare the ability of SRS with that of other conven-
tional imaging methods including ultrasound, CT, MRI and selective angiography to
localize primary and metastatic gastrinoma in 80 consecutive patients with the Zollinger-
Ellison syndrome [34].
Methods
All patients underwent SRS, CT, ultrasound, bone scanning, and MRI including
TI-weighted spin-echo sequences and STIR sequences as described previously [1, 11, 24,
35]. Selective angiography was performed with selective injection of splenic, superior
mesenteric, gastroduodenal and hepatic arteries as described elsewhere [1, 9, 10]. A sin-
gle radiologist evaluated the results of all conventional imaging methods. For SRS, all
patients received an intravenous injection of 6 mCi of [111In-DTPA,DPhel]octreotide.
Images were obtained at 4 hours and 24 hours post injection. (At 4 hours, a 30-minute
whole body scan, 10-minute planar spot views of the abdomen and SPECT [single-pho-
ton emission computed tomography] were done.) Repeated SPECT images were per-
formed at 24 hours. Results of SRS were obtained while the nuclear medicine radiologist
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was blinded to the results of the conventional imaging studies. All imaging studies were
evaluated in two separate aspects: whether a possible primary or extrahepatic tumor was
localized and whether hepatic metastases were found. All patients with suspected metasta-
tic disease in the liver underwent percutaneous biopsy. The results are expressed as per-
centage ofpatients in whom any extrahepatic or hepatic tumor was localized. Each patient
was counted only once (Table 1).
Results
CT, MRI or angiography identified extrahepatic tumors in 28 percent to 31 percent
and ultrasound detected extrahepatic tumors in 9 percent of patients (Table 1).
Extrahepatic tumors were detected in 58 percent (46/80) ofpatients with SRS only, which
was significantly more sensitive (p < .001) (Table 1) than any conventional imaging meth-
ods alone, and it was equally sensitive to all conventional imaging methods combined.
Figure 1, bottom, is an example of SRS localizing an extrahepatic gastrinoma in the pan-
creatic head area (i.e., a gastrinoma in a periduodenal lymph node was found at surgery)
in a patient in whom the CT scan (Figure 1, top) and other conventional imaging methods
were negative.
For localizing hepatic metastases in 24 patients with proven metastatic liver disease,
SRS was the most sensitive of any localization method in detecting metastases in 92 per-
cent (Table 1), and it was equal to all conventional imaging methods combined. Other
imaging studies were less sensitive with the exception of MRI (p = .12). Angiography
detected hepatic metastases in 62 percent ofpatients but was less sensitive than SRS (p =
.016) as was ultrasound which detected hepatic metastases in 46 percent (p = .001 vs.
SRS), and CT, which detected hepatic metastases in 42 percent (p < .001 vs. SRS) of
patients. Figure 2 (bottom) is an example ofthe high sensitivity ofSRS in detecting hepat-
ic metastases in a patient in whom the CT scan (Figure 2, top) and other conventional
imaging studies were negative.
Since we began using SRS at the NIH in June 1994, 31 patients underwent
exploratory laparotomy forpossible removal ofthe primary gastrinoma afterthe SRS and
Table 1. Ability of conventional imaging modalities and SRS to localize an extrahepatic gas-
trinoma or hepatic metastases in 80 patients with Zoilinger-Ellison syndrome.
Extrahepatic (n = 80) Hepatic (n = 24)
P value P value
(Compared (Compared
Imaging method Positive (%)2 to SRS) Positive (%)2 to SRS)
Ultrasound 9 <.001 46 .001
CT scan 31 <.001 42 <.001
MRI 30 <.001 71 NS
Angiography 28 <.001 62 0.016
All conventional combinedl 48 NS 83 NS
SRS 58 92
SRS and all other tests 68 NS 96 NS
Shown are results for 80 patients for localization of extrahepatic gastrinoma and 24 patients with
histologically proven liver metastases. Results from Ref. [24].
1All conventional results refer to results with ultrasound, CT scan, MRI and angiography.
2 Positive percent is the percentage of patients in the indicated disease extent category (i.e., extra-
hepatic or hepatic) with a positive result with the indicated imaging modality.
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Figure 1. CT scan and SRS ofa patient with localized gastrinoma. This patient (NIH#2789772)
is a 59-year-old male with a previous duodenal gastrinoma resection. His postoperative gastrin lev-
els remain elevated. His CT scan (top) shows no lesion. The SRS (bottom) shows an increased
uptake medial and anterior to the right kidney (arrow). At repeat surgery, a 6 mm gastrinoma in a
periduodenal lymph node was removed with subsequent normalization of serum gastrin levels. This
patient illustrates the increased sensitivity of SRS over conventional imaging studies (CT, ultra-
sound, MRI) in detecting extrahepatic gastrinomas, which has been reported in a number of recent
studies [15, 27, 28, 34, 56].
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Figure 2. CT scan and SRS of a patient with metastatic gastrinoma to the liver. This patient
(NIH #1897238) is a 75-year-old female with histologically proven metastatic disease to the liver.
The CT scan (top) shows no hepatic lesion. The SRS (bottom) shows two foci in the liver with one
focus in the right liver lobe (arrow) and one focus in the left liver lobe (arrow). This patient illus-
trates the increased sensitivity of SRS over conventional imaging studies (CT, ultrasound, MRI) in
detecting hepatic metastases and in demonstrating multiple metastases in different areas ofthe liver,
which can influence determinations ofpossible resectability [34, 56, 57].
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conventional imaging methods were performed. The results from 24 patients are shown
inTable 2. Twelve ofthese patients were fromthe 80 patients discussed above andreport-
ed recently [34] and 12 patients were more recent patients not included in the first 80
patients. Gastrinoma was found in all patients at surgery. A total of40 gastrinomas were
found: 13 gastrinomas in the duodenum, 3 in the pancreas and 24 in the lymph nodes.
Although the sensitivity ofSRS for localizing duodenal gastrinoma was low (38 percent)
when compared to localizing pancreatic gastrinomas (100 percent) and gastrinoma in
lymph nodes (88 percent), it was more sensitive than ultrasound, CT, MRI (0 to 8 per-
cent) and equal to angiography or all conventional imaging methods combined (31 per-
cent) (Table 2). For duodenal and pancreatic tumors, SRS had equal sensitivity to that
seen with all conventional imaging studies combined, but it was the more sensitive (88
percent) than a combination of all conventional imaging modalities in detecting gastri-
nomas in the lymph nodes (Table 2).
RELATIONSHIP OF NIH RESULTS OF SRS SENSITIVITY
COMPARED TO OTHER STUDIES IN PETS
Applicability ofNIH results to other PETs
The results ofour study likely have applicability to other less common PETs and car-
cinoid tumors for a numberofreasons. Gastrinoma resembles all PETs with the exception
ofinsulinoma in its biological behavior, growth pattern, histochemistry, rates ofthe occur-
rence of somatostatin receptors and malignant potential [2, 5, 6]. It resembles carcinoid
tumors in the above characteristics, especially in the important areas ofhaving ahigh den-
sity of somatostatin receptors, similar malignant potential and growth patterns [3, 13,14,
36, 37].
Comparison ofNIH results with SRS to thosefrom other studies
The results of other studies in patients with Zollinger-Ellison syndrome and other
PETs are compared with our study in Table 3. The imaging studies were compared by the
percentage ofpatients with apositive result and not on a lesion-by-lesion basis. For extra-
hepatic gastrinomas the sensitivity ofSRS was 56 to 80 percent (Table 3), which was more
Table 2.Ability ofconventional imagingstudies and SRS tolocalize gastrinomas (n = 40) found
at surgery in 24 consecutive patients.
Gastrinomas location at surgery (percent identified)
Duodenum Pancreas Lymph node
Imaging method (n = 13) (n = 3) (n = 24)
Ultrasound 0% 33% 13%
CT scan 8% 67% 38%
MRI 8% 67% 41%
Angiography 31% 100% 44%
All conventional combinedl 31% 100% 68%
SRS 38% 100% 88%
SRS and all other tests 62% 100% 95%
In the 24 patients, 13 duodenal gastrinomas, three pancreatic and 24 positive lymph nodes were
found at surgery. Results are the percentage of the gastrinomas in the indicated category localized
by the indicated imaging modality preoperatively.
I All conventional results refer to results with ultrasound, CT scan, MRI and angiography.
514Gibril andJensen: Localization ofGI endocrine tumors
0 6~~
PC
"0
0 0~~~~~
_0
C) C)~ ~ ~ ~ ~ ~~~~~~~~~~~C ~~Cu 0~
- ~~~~~~~~~ 0 ~~ ~ ~
0 C)~~~~~~~~~~~~~~~~~~0
Cu ~~~~~~~~~~~~~~~~~~~~~~~~~~~~C
C) O
"a~~o
Cu.C (*. - en 00e
- ci ~ N
l.a - a~~~~~~~~~~~~~~~~
"0
"0~~~~~~~~~~~~
0 ~ ~ ~ ~ ~ ~ ~~~~~~~~~00
co C0
I- - ~ ~ ~ ~ ~ 4 -
WI C) a~~~~~~~~~~~~~~~~~~~~~~nC
0~~~~~~~~~~~~~
Cu *~~~~~~~~~'-
C-,~~~~~~~~~~~~~~-
oa 00
515Gibril and Jensen: Localization ofGI endocrine tumors
'0
0~ ~~ ~ ~ ~ ~ ~ ~~0
4- H-
0~~~~~~~~~0
0~ ~~
.P.j ~ ~ ~ ~ ~ ~ ~
pa >oa
~~~~~~~~~~0
Cu~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~~~~~~~~C
~ ~ ~~ ~ ~~~~~~~~~~~~~~~~~C
40
'0C\00
PC
01 NC
0~~~~~~~~c
o~~~~~~~~~~c
516Gibril andJensen: Localization ofGI endocrine tumors
sensitive than other conventional imaging methods in the same study except CT (75 per-
cent) in one series [39]. However, other studies in which SRS was not performed report
higher sensitivities with CT and angiography than reported in most ofthe studies in Table
3 [1, 6, 40, 41]. For detecting metastatic gastrinomas, SRS has a 92 to 100 percent sensi-
tivity, which was more sensitive than other imaging studies (42 to 76 percent) (Table 3).
For series containing different PETs for the extrahepatic tumors, SRS was more sensitive
than ultrasound, MRI and CT in two out of three studies (Table 3, bottom). For identifi-
cation ofhepatic metastases in patients with various PETs, there is little data; however, in
one study [16], SRS was superior to CT, ultrasound or MRI (Table 3, bottom). For insuli-
nomas (Table 4, top) the sensitivity of SRS for detecting extrahepatic tumors was as low
as 20 percent to 46 percent, which was comparable with other imaging studies except
angiography (63 percent) and CT (71 percent) in two series. For carcinoid tumors (Table
4, bottom) there are not many studies that have compared SRS with other conventional
imaging methods with different disease extents [18]. The data shown in Table 4 demon-
strate that for carcinoid tumors the sensitivity of SRS and other conventional imaging
methods are equal, in general, for extrahepatic andhepatic metastases [38]; however, other
studies reported that SRS was more sensitive in detecting distal metastases [18].
COMPARISON OF THE RESULTS OF SRS AND EUS FOR
LOCALIZING VARIOUS PETS
A number ofrecent studies have reported that endoscopic ultrasound (EUS) is ahigh-
ly sensitive technique to localize PETs [15, 23, 25-33]. In Table 5, results are shown from
a comparison of SRS, EUS or CT in localizing various PETs from a number of studies,
and the studies are stratified according to the type of tumor. For duodenal gastrinomas,
there are little comparative data. Ofthe 11 duodenal gastrinomas in two studies, SRS rec-
ognized from 38 to 100 percent ofduodenal tumors andEUS from 63 to 67 percent. These
results suggest that both localization methods may miss a significant proportion of duo-
denal tumors. This possibility has been raised previously with EUS [42] and is consistent
with our recent data in which SRS only localized 38 percent of duodenal gastrinomas
(Table 2). Two recent studies [15, 27] suggest in gastrinomas for identification ofduode-
nal tumors orgastrinomas in lymph nodes that the combination ofboth EUS and SRS may
be better than either alone. Pancreatic gastrinomas are generally larger than duodenal gas-
trinomas [43] and are well seenby EUS [25,28, 29, 33] and by SRS [28] (Table 5). Recent
studies demonstrate that EUS is much more sensitive than SRS [23, 28] or conventional
imaging [29-33] for localizing pancreatic insulinomas. These data are consistent with
results of recent studies that demonstrate that insulinomas frequently have a low density
of high affinity octreotide receptors (sstr 2, 5) [28, 44] and, therefore, are not frequently
seen on SRS (Table 4). For all PETs of various types, the sensitivity of SRS was 52 per-
cent in one study (Table 5), EUS from 82 to 89 percent and CT scanning from 0 to 36 per-
cent in the different studies.
The exact relative role of EUS or SRS in patients with PETs at present is con-
troversial [42, 45]. This has occurred because there are few studies comparing EUS and
SRS in a large number of patients. However, the results summarized in Table 5 suggest
the following conclusions: First, for duodenal gastrinomas it is clear both studies miss a
proportion of these tumors. It remains unclear the exact percentage identified by each
modality, whether these studies identify sufficient numbers ofduodenal gastrinomas that
their use for this isjustified and whether the combination is better than either alone. This
is an important point because in recent surgical series duodenal gastrinomas are being
found more frequently than pancreatic gastrinomas [6, 27, 46-48]. Second, for pancreatic
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Table 5. Results ofEUS, SRS, or other modalities in various studies in detecting PETs.
Positive (percent)l
No. of SRS
tumorsa and EUS
Study Year Ref. orpatientsb CT scan SRS EUS combined
I. Duodenal gastrinoma
Cadiot
Zimmer
Ruszniewski
Thompson
1996 27
1996 28
1995 25
1994 26
8a 0 38
3a 0 100
loa 0
4a 0
63 88
67
50
0
II. Gastrinoma in lymph node alone or with duodenal tumor
Cadiot
Ruszniewski
Palazzo
1996 27
1995 25
1992 33
llb 0 73 55 91
8a 0 63
5a 0 100
III. Pancreatic gastrinoma
Zimmer
Rusniewski
Rosch
1996 28
1995 25
1992 29
ga 33 89 89
4a 25 75
7a 0 86
IV. Pancreatic insulinoma
Zimmer
Zimmer
Glover
Rosch
Palazzo
Ruszniewski
Lightdale
V. All PETs2
Zimmer
Rosch
Palazzo
Lightdale
1996 28
1994 23
1992 31
1992 29
1992 33
1995 30
1991 32
1994 23
1992 29
1992 33
1991 32
14a 21 14 93
8a 12 12 87
1Sa 20 80
31a 0 - 81
13a 0 77
9ga 10 89
4a 0 - 75
25a
37b
24a
ga
36 52 88
0 - 82
17 88
11 - 89
I Percent positive is the percentage of tumors found at surgery localized by the indicated imaging
modality pre-operatively.
2 All PETs means studies in which patients with different types ofPETs were combined.
"-" Means no data were reported for the localization method indicated.
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gastrinomas, both EUS and SRS appear to identify 75-100 percent likely because these
tumors are frequently large (i.e., >2 to 3 cm) [43]. It has, in fact, been recommended
recently thatEUS be routinely used in gastrinomas toexclude apancreatic tumor [26]. For
insulinomas EUS is clearly the procedure of choice. This conclusion is justified because
these tumors are almost always intrapancreatic [49], which increases the ability to locate
them on EUS, have a low density of high affinity somatostatin receptors that bind
octreotide and thus are not well seen on SRS using [111In-DTPA-DPhe1]octreotide. Also,
the tumors are frequently less than 1 cm and thus are not well seen on conventional imag-
ing studies because their ability to detect PETs decreases with decreasing tumor size [11,
24, 40, 41, 50]. Third, only limited studies are available on other PETs. However, because
most are intrapancreatic [2, 5], have a high density of somatostatin receptors similar to
pancreatic gastrinomas [13, 14, 51] and are usually large at presentation [2, 5, 52], both
SRS (50-60 percent) and EUS (40-70 percent) are likely more useful than conventional
imaging studies. The usefulness ofEUS in PETs that are notinsulinomas is limited by the
fact that in less than 30 to 40 percent ofpatients is its use indicated to localize the prima-
ry tumor [45]. This occurs because most patients with VIPomas, nonfunctioning PETs,
glucagonomas, somatostatinomas and GRFomas present with metastatic disease to the
liver, large primary tumors [2, 5, 53-55] and thus, location of the primary may be either
not difficult and can be easily accomplished with conventional imaging studies or is not
indicated because it will not alter management.
In conclusion, our recent NIH study [34] combined with other studies on gastri-
nomas and other PETs (Tables 3 and 4) demonstrate that SRS has greater sensitivity than
conventional imaging studies (ultrasound, CT, MRI, angiography) at localizing either the
primary tumor or hepatic metastases. In patients with carcinoid tumors, SRS has equal or
greater sensitivity to conventional imaging modalities in the two comparative studies
reported. Forinsulinomas, EUS has the greatest sensitivity and should be the initial imag-
ing study of choice. For the other PETs including gastrinomas, which are frequently
malignant, SRS should be the initial localization modality because of its sensitivity and
ability to examine the whole body at once. In the future, it will be important to establish
whether EUS or SRS is best for localization of the primary tumor for patients without
metastatic disease to the liver or whether they are complementary.
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